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Background: Patients with congenital heart defects (CHD) often present more challenges to pacing
therapy due to anatomy than those without CHD. The lumenless, 4.1Fr diameter M3830 pacing lead
(Medtronic, Inc., Minneapolis, MN, USA), approved for use in 2005, has, to date, reported to have
excellent short-term (<6 years) lead performance. Unfortunately, very long-term performance is unknown,
especially among CHD patients and with implants at alternate pacing (AP) sites. This study reports a
10-year clinical experience with the M3830 lead.
Methods: Records of patients who received the M3830 lead were reviewed: patient demographics,
implant techniques and locations, sensing and pacing characteristics, impedances (Imp), and any
complications at implant and follow-up.
Results: From 2005 to 2015, 141 patients (ages 2–50, mean 20.1 years, 57% males) received 212 leads:
atrial 115; ventricle 97. CHD was present in 62% of patients. Leads were inserted at AP sites in 96% of
patients. Postimplant follow-up was from 3 months to 10 years (mean 56.3 months). Comparative implant
versus follow-up values (mean ± standard deviation) were available on 196 leads (92.5%), showing
persistently low (<1 v @ 0.4–0.5 ms) pacing thresholds (P = 0.57). Sensing was also comparable (atrial
leads, P = 0.41; ventricular leads, P = 0.9). Impedances differed (P < 0.05) but remained within the normal
range. Two A leads became dislodged and one was repositioned while two other leads (1 A, 1 V) were
extracted. There are no differences observed in the pacing characteristics between the CHD and non-CHD
groups on follow-up.
Conclusions: The 4.1Fr lumenless pacing lead shows ease of implant regardless of CHD or AP site,
excellent very long-term (10 years) stability, and performance indices with a very low rate of complications.
(PACE 2017; 40:17–25)
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Introduction
The management of congenital heart disease
(CHD) patients continues to be challenging even
after surgical repair, which, due to conduction
system damage, often results in the need for life-
long pacing therapy. Due to the persistence of
altered anatomy and vascular issues, pacing lead
implantation is associated with more technically
demanding issues than among non-CHD patients.1
These issues are often compounded by small
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patient body sizes and vascular dimensions,
creating a high risk for venous obstruction,
reportedly ranging from 13% to 64% of patients.2–5
With the advances in technology, new pacing
lead designs have evolved over time, offering
benefits among challenging patient groups such
as those with CHD. Such new designs have
improved implantation/extraction at alternative
and often technically difficult sites to access,
while still assuring limited complications (e.g.,
dislodgements, fractures, and venous occlusions),
as well as causing adverse effects on valves and
vasculature.6
One of the newest designs is the lumen-
less, 4.1Fr diameter, steroid-eluting, coaxial,
solid core, nonstylet, catheter-delivered lead
(M3830, Medtronic, Inc., Minneapolis, MN, USA).
Approved for use in the USA in 2005, the
flexible catheter-delivery technique permits ease
of implant at traditional (appendage/apex) as well
as nonapical and appendage locations. These
©2016 Wiley Periodicals, Inc.
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latter locations can improve paced myocardial
function.7 Although relatively short-term perfor-
mances (<6 years, mean 2 years) have been
published, very long-term efficacy of this lead
design has not been reported, especially among
CHD patients and with implant at alternate
(nonappendage/apex) pacing (AP) sites.8,9
This study is a retrospective review of chronic
M3830 lead performance indices at a single
congenital heart center from 2005 to 2015. It
presents the longest postimplant (up to 10 years
postimplant, mean 56.3 months) evaluation of this
lead’s pacing and sensing performances, in all
age patients, and any complications as well as
extraction concerns among patients with normal
anatomy as well as various pre- and postrepair
congenital heart defects.
Materials
The Medtronic M3830 lead is a lumenless
active fixation, bipolar, steroid-eluting (initially
declomethasone, changed to beclomethasone after
2012) helical design lead. The 4.1-Fr isodiametric
lead body has a solid core with an exposed helix.
Removal of the central lumen, necessary for stylet-
delivered leads, effectively reduces the diameter
up to 40% of a standard 5-7-Fr pacing lead, permit-
ting transvenous pacing among younger patients,
especially those with repaired or unrepaired con-
genital heart defects.10 The M3830 lead employs a
central cable conductor coil with silicone inner
and polyurethane outer insulations, available
in 49–59–69-cm lengths. The use of composite
insulation material (polyurethane plus silicone)
not only contributes in diameter reduction, but
also results in improved crush resistance and ease
of insertion through the accompanying delivery
catheter, an 8.4Fr diameter steerable slice-away
sheath (SelectSecureTM), which has kink-resistant
properties. The flexibility of this kink-resistant
catheter permits from 22 to 44 cm long curves,
which facilitate implant at select and alternate
sites, including septal, left atrial, and outflow
regions, which greatly facilitate implant in some
more complex CHD anatomies (Fig. 1). In addition,
use of smaller diameter introducer sheaths or
direct insertion without use of any sheaths as well
as a transatrial approach have been successfully
reported.1,11,12
Methods
This study is a retrospective review of
the M3830 lead performance indices (sensing
and pacing thresholds, impedances), as well
as any technical implant or explant issues,
from January 2005 to December 2015. The
institutional review board at The Children’s
Hospital of Michigan/Wayne State University
Figure 1. Fluoroscopic (AP view) comparative appear-
ance of the 4.1Fr M3830 lead (A) and more standard
6Fr lead (B) implanted in the venous left atrium and
ventricle in a patient following the Mustard atrial baffle
repair for D-TGA. The smaller diameter of the M3830
lead is readily apparent. Lead implant at the roof of the
left atrium, and avoidance of phrenic nerve stimulation,
was easily achieved by use of the flexible delivery
catheter which is able to overcome the acute angle often
caused by an intravascular stent placed in the superior
Mustard baffle (arrow).
School of Medicine approved the study. Inpatient
and outpatient charts and electronic records
were reviewed. Patient demographics, congenital
cardiac anatomies, surgical repairs, lead implant
sites, lead sensing, and pacing properties at
implant and follow-up clinic visits were collected.
Complications at the time of implantation as
well as during follow-up requiring lead extrac-
tion/revision were also recorded. All patients had
a predevice implant echocardiography/Doppler
study.
Implant technique: As previously described,
following a standard sterile surgical pacemaker
implantation protocol, either the left or right
subclavicular approach, was used.9 Initially, a
standard right and left heart catheterization
study was performed on all patients from the
femoral approach to include evaluation of vascular
patency and access routes to ascertain any
leaks/shunting that might require closure or
vessel/baffle narrowing that might require stent
placement prior to lead implant. For all patients,
optimal lead pacing and sensing characteris-
tics were achieved. Physiologic optimization of
paced-contractility at all sites was under-
taken by comparative online measurements of
the systemic ventricle’s contractility indices
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(dP/dt-max) at various potential implant sites
along the ventricular septum for ventricular
pacing, and at the atrial-free wall or septum
for atrial pacing. Two-dimensional, color-guided
spectral Doppler, and tissue Doppler imaging of
left atrial ejection fraction determined the choice
of atrial implant sites.13 The subclavian vein was
entered using the standard needle approach. Most
implants utilized the SelectSecureTM catheter de-
livery system. Other implant variations included
use of smaller diameter introducers depending on
patient size and anatomy as well as the trans-
atrial approach to ventricular lead implant.12
All Model 3830 leads were positioned without
difficulty. Standard measurements of sensing and
pacing indices were recorded in each instance.
Since this was a new lead design and deliv-
ery system when first introduced, fluoroscopy
times for lead implant were initially recorded.9
Following implanter familiarity with this lead,
however, continued recording of specific implant
times was not routinely performed. All single
ventricle patients were routinely treated with
aspirin/coumadin depending on any recurrent
clinical flutter. Postdevice implant, anticoagula-
tion therapies were not modified.
Patients were followed in the electrophysiol-
ogy clinic at the Children’s Hospital of Michigan
section of Cardiology at regular intervals per
protocol. Pacemaker checks were performed at
these visits to record each lead’s performance
indices. These records were kept in the pacemaker
charts as well as recorded electronically in the
patients’ electronic records.
Statistics: Data were analyzed using the
GraphPad software QuickCalcs using exact
Fisher’s test and paired t-test with P-value <0.05
considered statistically significant.
Results
Performance data on all 212 leads (115
atrial; 97 ventricular) from 141 patients was
reviewed. Patients (57% males) ranged in age
from 2 to 50 years (mean 20.1 years). Both
pre- (27%) and postrepair (73% of patients)
CHD included septal defects, tetralogy of Fallot,
and transposition of the great arteries [TGA;
both dextro (D) and levo (L)] (Table I). Leads
were implanted at AP sites in 96% of patients
including, but not restricted to, the right atrial
septum, ventricular septum, and left atrium/left
ventricle (D-TGA with the Mustard intra-atrial
baffle repair). Among patients with single ventricle
anatomy, both the classic atrio-pulmonary and
lateral tunnel surgical “Fontan” procedures had
been performed. Among those with the lateral







Implant age in years (mean) 2–50 (20.1)
Male: female 81:60 (57.5%: 42.5%)
Normal cardiac anatomy 53/141 (38%)
CAVB 33/53 (62%)
Cardiomyopathy 9/53 (17%)
Long QTc 7/53 (13%)
Ventricular tachycardia 4/53 (8%)
Structural CHD 88/141 (62%)
D-TGA 30/88 (34%)
TOF 14/88 (16%)
Single ventricle physiology 11/88(12.5%)
VSD 8/88 (9%)
AS/aortic or mitral valve
replacement
8/88 (9%)




AS = aortic stenosis; ASD = atrial septal defect; AV =
atrioventricular; CAVB = complete atrioventricular block; CHD =
congenital heart defects; D-TGA = dextro-transposition of the
great arteries; L-TGA = levo-transposition of the great arteries;
TOF = tetralogy of Fallot; VSD = ventricular septal defect.
was achieved by lead insertion at the atrial
remnant along the cavopulmonary anastomosis14
(Fig. 2). One patient with complex CHD (hypoplas-
tic right ventricle, bilateral “Glenn” pulmonary
artery connections, and atrial septal defect) with
fractured epicardial leads, underwent a transatrial
ventricular implant approach (Fig. 3).
All leads were implanted without complica-
tions with standard follow-up clinical evaluations.
More than 50% of patients were followed for
greater than 5 years postimplant. Data on all
212 leads showed the implant pacing threshold
(mean ± standard deviation) (at 0.4–0.5 ms) to be
0.69 ± 0.32 v. Comparative follow-up data at more
than 3 months to 10 years (mean 56.3 months)
could be obtained on 196/212 leads (92.5%):
106 atrial and 90 ventricular leads. Patients with
the remaining 16 leads were lost to follow-
up (<3 month follow-up) or died soon after
implant for nonpacemaker-related issues. There
was no evidence of lead failure. Pacing thresholds
(measured in volts at 0.4–0.5-ms pulse width)
remained persistently low for all the 196 leads for
which chronic data were available. When taken
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Figure 2. Fluoroscopic (AP) view of a M3830 lead
implanted at the atrial remnant site in a patient
following the lateral tunnel “Fontan” repair for a single
ventricle. There was an absent innominate vein with a
left superior vena cava opening into the venous atrium.
The lead was easily positioned and secured in a very
small area of electrically active residual atrial tissue
that permitted effective pacing and sensing. Note a
stent (arrow) in the aorta at the site of a previous
coarctation.
Figure 3. Fluoroscopic (right anterior oblique) view of
a M3830 lead placed via a transatrial approach into a
hypoplastic right ventricle. A larger 6Fr diameter lead is
secured to the atrium. Note the spider-like CardiosealTM
atrial septal defect closure device.
as a whole, there was no significant difference
in thresholds: 0.69 ± 0.31 v (at implant) versus
0.67 ± 0.35 v (at last follow-up) (P = 0.57).
When these data were divided into chamber
paced, atrial (A) lead thresholds either remained
constant or showed some decrease (P < 0.05)
at certain postimplant intervals. In comparison,
individual ventricular (V) lead thresholds either
remained consistent or showed a specific time-
interval increase (P < 0.05) when compared with
implant values, but remained <1 v (Fig. 4). Both
P and R wave sensing remained stable over
the duration of the study (Fig. 5). As seen in
Table II, when all leads were taken as a whole,
comparing implant with the most recent follow-
up data, sensing characteristics were comparable
from implant throughout the study: P waves [mean
3.65 ± 1.95 vs. 3.63 ± 2 mv (P = 0.93)] and R waves
[10.5 ± 5.5 vs. 9.9 ± 4.8 mv (P = 0.41)]. When leads
were serially compared over years of follow-up,
there were changes in impedances [atrial: 745 ±
226 vs. 553 ± 119  and ventricular: 847 ± 254 vs.
521 ± 80  (P < 0.0001)] but all within the normal
range (350—1,500 ) for this particular structural
design. There was no evidence of conductor coil
fracture nor insulation breaks.
On comparison of patients who had structural
CHD (62%) with those who had a structurally
normal heart (38%), no differences were found in
the sensing characteristics. P waves [mean 3.46 ±
2 mv vs. 3.82 ± 2 (P = 0.37)] and R waves [8.7 ±
4.7 mv vs. 10.75 ± 5.3 (P = 0.08)]. There was also
no significant difference in thresholds observed at
the last follow-up: atrial leads: 0.61 ± 0.4 v (non-
CHD patients) vs. 0.58 ± 0.32 v (CHD patients)
(P = 0.65) and ventricular leads: 0.77 ± 0.3 v (non-
CHD patients) vs. 0.71 ± 0.35 v (CHD patients)
(P = 0.45). All the impedances were in the normal
range and no differences were observed between
either the atrial (566.9 ± 141 vs. 532 ± 62.8; P =
0.13) or ventricular leads (525 ± 76.5 vs. 515.3 ±
86.4; P = 0.57).
Complications, in the form of dislodgement,
were minimal (1%). Two A leads became dis-
lodged <1 month postimplant, both associated
with excessive patient arm and shoulder activity.
Both the leads were implanted in the right atrial
septal position. One was abandoned and the
other was repositioned using a custom-made tool
design.15 Two other leads (1 A, 1 V) were extracted
at the time of the initial device exchange to
an implantable cardioverter defibrillator, 4 years
after the M3830 leads were implanted. Of note,
extraction by simple traction of neither lead was
possible due to excessive adhesions along the
innominate-superior vena cava region. Extraction
was then successfully performed by use of an 8Fr
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Figure 4. Pacing thresholds. (A) Atrial voltage thresholds (mean ± SD) measured at 0.4–0.5 ms, from implant over
time with the number of leads for each follow-up period indicated. Lower thresholds (P < 0.05) were observed at the
0–2 years and 6–8 years follow-up intervals (marked by *). Overall mean threshold values were <1 v. (B) Ventricular
voltage thresholds (mean ± SD) measured at 0.4–0.5 ms, from implant over time with the number of leads for
each follow-up period. Higher mean thresholds (P < 0.05) were observed at the 0–2 years and 4–6 years follow-up
(marked by *). Overall, mean threshold values were <1 v. SD = standard deviation. [Color figure can be viewed at
wileyonlinelibrary.com]
counter traction catheter (Yellowbird, Cook, Inc.,
Bloomington, IN, USA).
Discussion
With the technical advances in the pacing lead
designs, physicians are moving toward placement
of transvenous pacemakers in younger patients
and also in CHD patients.16–24 However, this
unique population poses numerous challenges
for stable, long-term pacing success.25 These
include a smaller patient size and thus smaller
vascular calibers, diverse venous anatomies, and
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Figure 5. Sensing performances. (A) Atrial P wave (mean ± SD) sensing (mV) over time with the number of leads
for each follow-up period (parenthesis). No significant changes were observed at any specific follow-up period.
(B) Ventricular R wave (mean ± SD) sensing (mV) over time with the number of leads for each follow-up period
(parenthesis). No significant changes were observed at any specific follow-up period. SD = standard deviation. [Color
figure can be viewed at wileyonlinelibrary.com]
structural defects and various repairs, which can
alter normal anatomy. All of these factors can
complicate and even prohibit typical delivery and
lead positioning techniques. In addition, somatic
growth and active patient lifestyles can affect lead
stability.20,23 Another challenge to implant is the
achievement of select site placement to improve
paced myocardial function, with stylet-delivered
leads.9,10,26,27
The relatively new, lumenless, 4.1Fr diameter
pacing lead (Medtronic Inc.) has gained particular
attention in pediatric/congenital heart cardiology
centers as it appears to minimize complications
typically associated with standard transvenous
leads, especially among younger patients, as noted
in this study, and to provide potential advantages
in CHD and pediatric patient population due
to its specific design. This lead is an active
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Table II.
All Leads Performance Indices*@
Atrial Leads (mean ± SD) (n = 115) Ventricular Leads (mean ± SD) (n = 97)




0.73 ± 0.3 0.6 ± 0.35 0.0029 0.64 ± 0.32 0.75 ± 0.34 0.0063
Sensed P/R wave
(mv)
3.65 ± 1.95 3.63 ± 2 0.93 10.5 ± 5.5 9.9 ± 4.8 0.41
Lead impedance
(ohms, )
745 ± 227 553 ± 119 <0.0001 847 ± 254 521 ± 80 <0.0001
*mean ± SD; at implant and follow-up values are composites of all leads obtained at implant and most recent postimplant interval. SD =
standard deviation.
fixation, bipolar, steroid-eluting (currently lipid-
soluable beclomethasone) design with a solid
core. It is the thinnest diameter lead currently
available. With the growing population of adult
patients with CHD, the demand for small diameter
pacing leads has increased and, therefore, the
lumenless, nonstylet delivered coaxial leads
offer improved implant capabilities and crush
resistance.10
A potential advantage of the lead is the
ease of implantation, stability, and electrode
securing capabilities at alternate pacing sites.
This is especially important among CHD patients.
Previous studies have demonstrated that chronic
pacing at the more traditional ventricular apical
or atrial appendage implant sites can adversely af-
fect myocardial function.7,28 Additionally, among
CHD patients even with repaired hearts, the
traditional implant sites may be difficult if not
impossible to attain for effective pacing.29 For
example, the right atrial appendage is often
amputated following bypass cannulation and
ventricular-pulmonary conduits may distort the
apex. Short-term experience with this M3830
lead in patients with CHD at traditional pacing
sites, as well as alternative pacing sites, has
been promising.30 Device implant among repaired
congenital heart patients can be challenging. In
the current era, with fewer diagnostic cardiac
catheterizations being performed, compared to the
pre-2D echocardiography era, catheter manipula-
tion skills may require extra learning. However,
once mastered, in our experience, this catheter-
delivered lead surpasses the older stylet-delivered
leads, especially in attempting to achieve the more
patient-beneficial “alternate site” implants which
previously often required multiple attempts to
form the most appropriate stylet curves. In two
previous studies, fluoroscopy times for the M3830
lead implant ranged from 0.45 to 9 minutes (mean
1.6 ± 1.3) and 1.8 to 90 minutes (mean16.2 ±
14.7).8,9
In this report, >95% of the leads were
implanted at alternate pacing sites (i.e., right atrial
septum or left atrial-free wall, right or left ventric-
ular septum, and atrial remnants among patients
having undergone the lateral-tunnel “Fontan”)
with excellent pacing/sensing results and minimal
complication rates for a postimplant interval of
5 years (follow-up data available for >50% of the
patients) and 10 years (follow-up data available
for >20% of the patients). Although “His-” and
“para-His-bundle” pacing has been reported with
this lead, thresholds are often much higher than
at other septal sites, indicating a problem more
with the implant site than lead characteristics.31
Since the maintenance of low thresholds, and
associated low generator outputs which extend
battery longevity, is paramount when considering
pacemaker therapy in the young, this particular
site was purposely not utilized. Another favorable
aspect of the use of this lead is its improved
clinical benefits on the integrity of atrioventricular
valves and venous channels, reducing the rate
of valvular insufficiency and venous obstruction
when compared to the more traditional and larger
diameter leads.6
As noted above, although a few studies have
been published which report on the short-term
performance of the M3830 pacing lead since its
approval, the very long-term evaluation is still
unknown. This limits the knowledge of chronic
efficacy and also any complications that may or
may not arise in association with this design,
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placement, and extraction. A recent retrospective
study compared the M3830 with a different lead
(M1488, St. Jude Medical Inc., St. Paul, MN,
USA) over a 6-year (mean 26 months) interval.
The report demonstrated similar efficacy of both
leads among children and CHD patients but with
different complication rates: 5% among patients
who received the M3830 as compared to 20%
among those who received the M1488 lead, as
well as easier maneuverability of the M3830.
Of note, and different from this current report,
nine leads were extracted successfully by use of
only manual traction without the need for tools.8
However, the average postimplant duration was
1.37 years. Unfortunately, although that study
did indicate that at least one extraction was
in a patient with a dual-chamber system, time
after lead implant was not indicated. Therefore,
presence of a dual-chamber system, as seen in
our experience, may compound and accelerate
any lead-endothelial interactions, negating simple
extraction without tools. Further evaluations of
vascular effects on the M3830 lead are required
before any definitive assessments of lead-vascular
interactions and extraction can be made.
Results of this current report are similar
to those from a previous study demonstrating
the 5-year postimplant performances indices of
the M3830 lead compared with more traditional
stylet-delivered leads. This latter study focused
particularly on the efficacy and stability of the
M3830 leads implanted at alternate pacing sites
and concluded that performance indices were
comparable.9 A few smaller studies that were
done among CHD patients, with limited follow-
up intervals, also demonstrated impressive perfor-
mance of the lead with excellent pacing/sensing
thresholds and normal impedance values.26,27,29,32
To date, most studies done on the performance
evaluation of M3830 leads have demonstrated a
low to acceptable rate of complications related
to the lead implant, comparable to traditional
leads.
However, the information about complica-
tions related specifically to M3830 lead is limited.
A case report addressed the issue of difficult
repositioning after dislodgement of the lead,
due to the absence of an internal stylet, which
facilitates the lead repositioning. This necessitated
fabrication of an innovative tool design.15 That,
perhaps, is the one potential shortcoming of this
lead: lack of ease of repositioning in instances of
dislodgement. Fortunately, dislodgement was not
a prominent feature during this 10-year follow-
up study. One of the original multicenter studies
reported problems related to lead placement at a
follow-up interval of 3 months which included
elevated pacing thresholds (0.5%), failure to
sense (0.5%), pericardial effusion (0.6%), cardiac
tamponade (0.2%), and lead dislodgement (2.3%).
Some of these complications were related to the
lead placement technique. The most frequently
observed complication among previously pub-
lished reports was lead dislodgement.10,30 In this
study, only two of the 115 atrial leads (1%) and
no ventricular leads became dislodged. Implant
technique may be a definitive factor with implant
experience contributing to more lead stability. The
observed differences in lead impedances seen in
this study are typical of most chronic lead studies
and reflect more on intrinsic characteristics of
electrical conductance, not any lead problem,
per se. Likewise, changes in voltage thresholds,
although different over time, and associated
patient growth remained well within acceptable
values of 1 v.
Conclusion
With the improved care and management
of patients with congenital heart defects, there
has been an increase in the adult population of
patients with CHD, thus increasing the demand
of more maneuverable pacing leads that permit
fixation at sites other than right ventricular apical
or atrial appendage locations. Thinner diameter
leads with improved stability add additional
benefits of less adverse effects on valves and
vasculature, which are important in the young.
The novel 4.1-Fr diameter lumenless pacing
lead is unique in its design compared with
more traditional lead designs (5-7Fr), permitting
transvenous pacing in young patients with or
without CHD with limited adverse valve and
vascular problems. The provided catheter-based
delivery of the lead has resulted in improved
maneuverability and low complication rates when
compared to the more conventional leads. In
addition, the M3830 lead can be inserted with
none or smaller diameter catheters. In this
study, the 4.1Fr diameter, lumenless pacing lead
exhibited ease of implant regardless of CHD or site,
excellent very long-term (up to 10 years) stability,
and performance indices with a very low rate of
complications.
Study Limitations
This is a retrospective study that analyzed
pacing lead data available for patients followed
at a single tertiary cardiac center with implant
by established physicians who were very familiar
with the lead’s characteristics. Further multicenter
studies with implant by various physicians of
different skill sets are needed, possibly with
comparisons with various other leads, to further
assess the efficacy of this pacing lead in more
diverse patient populations and clinical settings.
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Nevertheless, the M3830 lead design shows
exceptional long-term performance in the very
complex and diverse as well as aging congenital
heart patient population.
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